Results of the Combined General Meeting of May 28, 2020
All ordinary and extraordinary resolutions have been adopted
Paris, (France), Cambridge (Massachusetts, United States), May 28, 2020, 6:00
p.m. CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company specialized in the development of drug candidates for
treatment of aged related diseases, amongst which neuromuscular diseases, today
announces the approval by a very large majority of all resolutions falling
within the remit of the Combined General Meeting.
Biophytis' combined General Meeting took place today behind closed doors, due
to measures imposed in the context of the COVID-19 pandemic. The 1,453
shareholders taking part in the vote owned collectively 9,779,269 shares, i.e.
a quorum of 23.57% and 20.87% of the voting rights.
The shareholders approved by a very large majority all the 21 resolutions
within the competence of the Combined General Meeting, in particular those
ratifying the unconsolidated and consolidated accounts for fiscal year 2019 and
the allocation of profit for the fiscal year ended December 31, 2019 as well as
Stanislas Veillet, President and CEO of Biophytis, said: "I am very pleased
that all the resolutions of the Combined General Meeting were approved by a
very large majority. I would like to warmly thank all 1,453 shareholders for
their exceptional commitment that made it possible for us to hold this General
Meeting and for their confidence in Biophytis by supporting by more than 90%
each resolution put to the vote."
The results of the votes of the combined General Meeting will be available on
Biophytis' website from June 1, 2020, under the section - Investors - Regulated
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age- related diseases, especially
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The
company plans to start the clinical development (MYODA) in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus). The Company has received approval from the Belgian Regulatory
Authority (FAMHP) to begin the Phase 2/3 clinical trial (COVA) with Sarconeos
(BIO101), evaluating it as a potential treatment for respiratory failure
associated with Covid-19. The Company also filed clinical trial applications
with the FDA in the US, MHRA in the UK and the French regulatory agency, ANSM
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS-ISIN: FR0012816825). For more information www.biophytis.com.
This press release contains forward-looking statements. While the Company
considers its projections to be based on reasonable assumptions, these
forward-looking statements may be called into question by a number of hazards
and uncertainties, so that actual results may differ materially from those
anticipated in such forward-looking statements. For a description of the risks
and uncertainties likely to affect the results, BIOPHYTIS' financial position,
performance or achievements and thus cause a change from the forward-looking
statements, please refer to the "Risk Factors" section of the Company's 2018
Annual Report available on BIOPHYTIS website ( www.biophytis.com).
This press release, and the information contained in it, does not constitute an
offer to sell or subscribe, nor the solicitation of a purchase or subscription
order, of BIOPHYTIS shares in any country. The elements contained in this
communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from
those anticipated in this information due to different risk and uncertainty
factors. This press release was written in French and English; If there is a
difference between the texts, the French version will prevail.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO